2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Non-Biological Therapies, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, CLL, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

2122 Real-world comparison of biologic features, treatment patterns, and clinical outcomes between younger (≤55 years) and older (>55 years) patients with CLL receiving frontline targeted therapy

Daniel A. Ermann, MD, Hannah Willis, BS2, Xiaoyan Wang, MS3, Harsh Rohit Shah, DO4, Lindsey Fitzgerald, MD5, Kelsey Baron, MD6, Allison Marie Bock, MD7, Narendranath Epperla, MD, MS, FACP8, Boyu Hu, MD9, Deborah Stephens, DO10, Ahmed Sawas, MD11, Adam Kittai, MD12
1 Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States
2 University of Utah School of Medicine, Salt Lake City, Utah, United States
3 Flatiron Health, New York, New York, United States
4 Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States
5 Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States
6 Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States
7 Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States
8 Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States
9 Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States
10 University of North Carolina, Chapel Hill, North Carolina, United States
11 Flatiron Health, New York, New York, United States
12 NYU Langone Health, New York, New York, United States

Background:

Chronic lymphocytic leukemia (CLL) predominantly affects older adults. Patients (pts) aged ≤55 years represent <10% of those diagnosed with CLL and remain understudied. Given their longer life expectancy, greater potential for cumulative treatment exposure, and the increasing availability of effective targeted therapies, understanding how disease biology, treatment patterns, and long-term outcomes differ from those of older pts is particularly important. Therefore, we compared the clinical and biologic characteristics, frontline (1L) treatment patterns, and real-world outcomes of younger and older pts with CLL in a large nationwide cohort.

Methods:

This study utilized the US-based Flatiron Health Research Database, an electronic health record-derived, de-identified database. Adult pts with CLL who initiated 1L treatment with a Bruton’s tyrosine kinase inhibitor (BTKi: ibrutinib, acalabrutinib, or zanubrutinib) or B-cell Lymphoma 2 inhibitor-based therapy (BCL2i: venetoclax +/- obinutuzumab or rituximab) between 01/2019 and 01/2026 were included. Pts were categorized by age at treatment initiation as younger (18–55 years) or older (>55 years). Baseline characteristics and biomarker profiles at treatment initiation were compared. Overall survival (OS) and time to next treatment (TTNT) were estimated using Kaplan-Meier methods. TTNT was defined as the time from initiation of 1L therapy to the start of second-line therapy or death. Multivariable Cox regression models adjusted for sex, race/ethnicity, practice type, ECOG performance status, year of treatment initiation, Rai stage, biomarker status, and 1L treatment type.

Results:

Of 6,814 pts receiving 1L therapy, 520 (7.6%) were aged 18–55 years and 6,294 (92.4%) were aged >55 years. Median age was 51 years (47–53) in the younger cohort and 73 years (66–79) in the older cohort. Compared with older pts, younger pts more frequently had Rai stage II-IV disease (44.5% vs 31.2%), were of Black race (15% vs 8.2%), had an ECOG of 0 (52% vs 39%), and more often received 1L BCL2i-based therapy (30% vs 20%). In pts with available prognostic testing, younger pts had higher rates of unmutated IGHV (59% vs 54%; p=0.020) and deletion 11q (21% vs 17%; p=0.019), but lower rates of TP53 mutation (8.1% vs 17%; p=0.005), deletion 17p (8.5% vs 12%; p=0.044), trisomy 12 (21% vs 26%; p=0.007), and deletion 13q (44% vs 47%; p=0.034) compared with older pts.

With a median follow-up of 40 months (mo) in younger pts and 32 mo in older pts, median OS was not reached (NR) in either cohort. During follow-up, there were 29 deaths (5.6%) in the younger cohort and 1,406 deaths (22.3%) in the older cohort. Estimated OS at 5-years was 92% (95% CI, 90%–95%) in younger pts compared with 69% (95% CI, 67%–70%) in older pts (p<0.001). Median TTNT was 5.1 years (95% CI, 4.6–NR) in younger pts and 4.1 years (95% CI, 3.9–4.2) in older pts (p<0.001). The 5-year TTNT rate was 52% (95% CI, 47%–59%) in younger pts and 43% (95% CI, 41%–45%) in older pts.

On multivariable analysis, age >55 years remained independently associated with inferior OS (adjusted hazard ratio [aHR], 3.87; 95% CI, 2.67–5.59; p<0.001) and shorter TTNT (aHR, 1.22; 95% CI, 1.04–1.42; p=0.010). ECOG performance status ≥2 was also associated with inferior OS (aHR, 3.65; 95% CI, 3.08–4.32) and shorter TTNT (aHR, 2.02; 95% CI, 1.77–2.31). Across the entire cohort, BCL2i-based therapy was associated with longer TTNT compared with BTKi therapy (aHR, 0.70; 95% CI, 0.62–0.77; p<0.001), but not with a significant difference in OS (aHR, 0.93; 95% CI, 0.80–1.07; p=0.3).

Conclusions:

To our knowledge, this is the largest real-world analysis comparing younger and older pts with CLL initiating 1L targeted therapy. Pts aged ≤55 years represented only 7.6% of the cohort and were more likely to have higher Rai stage, unmutated IGHV status, be of Black race, and receive BCL2i-based 1L therapy. While younger pts had longer TTNT and OS, these findings should be interpreted cautiously given the potential influence of age-related competing mortality. Overall, these results suggest there are observable differences in disease biology among younger pts with CLL treated in the targeted therapy era. Future research should investigate the biologic basis of these differences to better understand the developmental pathogenesis of CLL and how it may influence optimal treatment selection in these rare patients.

Daniel A. Ermann, MD: BeOne Medicines, Ltd - Honoraria; BeOne Medicines, Ltd - Consultancy (Includes expert testimony); Eli Lily - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Astrazeneca - Consultancy (Includes expert testimony)